Literature DB >> 2501025

Resistance to etoposide induced by three glucose-regulated stresses in Chinese hamster ovary cells.

C S Hughes1, J W Shen, J R Subjeck.   

Abstract

The induction of glucose-regulated proteins by a variety of specific inducers leads to an increase in resistance to Adriamycin (Shen et al., Proc. Natl., Acad. Sci. USA, 84: 3278, 1987). In this study we examine several additional agents for cross-resistance induced during a glucose-regulated response in an attempt to better define the mechanism through which this phenomenon occurs. When anoxia, calcium ionophore A23187, or 2-deoxyglucose are used, a substantial resistance is obtained against the topoisomerase II-targeted agent, etoposide. Partial resistance is induced against vincristine and actinomycin D. Glucose-regulated protein inducers do not substantially alter cellular response to either bleomycin or radiation. In the case of mitomycin C there is a cellular sensitization with anoxia and 2-deoxyglucose while calcium ionophore A23187 had no effect on survival. This study suggests that the resistance obtained during a glucose-regulated response against etoposide and Adriamycin may involve topoisomerase II.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2501025

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

Review 1.  The unfolded protein response and cancer: a brighter future unfolding?

Authors:  Peter Scriven; Nicola J Brown; A Graham Pockley; Lynda Wyld
Journal:  J Mol Med (Berl)       Date:  2007-01-10       Impact factor: 4.599

2.  Modulation of gyrase-mediated DNA cleavage and cell killing by ATP.

Authors:  T K Li; L F Liu
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 3.  High molecular weight stress proteins: Identification, cloning and utilisation in cancer immunotherapy.

Authors:  Xiang-Yang Wang; John R Subjeck
Journal:  Int J Hyperthermia       Date:  2013-07-05       Impact factor: 3.914

4.  Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.

Authors:  G J Finlay; K M Holdaway; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma.

Authors:  Uwe Haberkorn; Johannes Hoffend; Kerstin Schmidt; Annette Altmann; Gabriel A Bonaterra; Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Michael Eisenhut; Ralf Kinscherf
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-15       Impact factor: 9.236

6.  Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.

Authors:  P B Jensen; H Roed; M Sehested; E J Demant; L Vindeløv; I J Christensen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells.

Authors:  W Tirasophon; A A Welihinda; R J Kaufman
Journal:  Genes Dev       Date:  1998-06-15       Impact factor: 11.361

8.  Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose?

Authors:  Nicola Di Santo; Jessie Ehrisman
Journal:  Cancers (Basel)       Date:  2013-09-10       Impact factor: 6.639

9.  UPR-induced resistance to etoposide is downstream of PERK and independent of changes in topoisomerase IIα levels.

Authors:  Melissa J Mann; Ethel R Pereira; Nan Liao; Linda M Hendershot
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

10.  Activation and clinical significance of the unfolded protein response in breast cancer.

Authors:  P Scriven; S Coulson; R Haines; S Balasubramanian; S Cross; L Wyld
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.